Denali Therapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 10 | -$0.69 | -$0.69 | -$0.69 |
| Q2 2024 | 6 | -$0.70 | -$0.70 | -$0.70 |
| Q3 2024 | 14 | -$0.75 | -$0.45 | -$0.60 |
| Q4 2024 | 6 | -$0.61 | -$0.61 | -$0.61 |
| Q1 2025 | 7 | -$0.73 | -$0.73 | -$0.73 |
| Q2 2025 | 7 | -$0.68 | -$0.68 | -$0.68 |
| Q3 2025 | 13 | -$0.64 | -$0.64 | -$0.64 |
| Q4 2025 | 7 | -$0.66 | -$0.66 | -$0.66 |
Denali Therapeutics Inc. Earnings Date And Information
Denali Therapeutics Inc. last posted its earnings results on Thursday, August 1st, 2024. The company reported $-0.59 earnings per share for the quarter, topping analysts' consensus estimates of $-0.68 by $0.09. The company had revenue of 0 for the quarter and had revenue of 330.53 M for the year. Denali Therapeutics Inc. has generated $-1 earnings per share over the last year ($-1.06 diluted earnings per share) and currently has a price-to-earnings ratio of -11.12. Denali Therapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based on prior year's report dates.
Denali Therapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/01/2024 | Q2 2024 | -$0.68 | -$0.59 | 0.09 | $10.00 M | $0 |
| 05/07/2024 | Q1 2024 | -$0.67 | -$0.68 | -0.01 | $0 | |
| 02/27/2024 | Q4 2023 | -$0.86 | $-305,043,000 | |||
| 11/07/2023 | Q3 2023 | -$0.83 | -$0.72 | 0.11 | $11.16 M | $1.27 M |
| 08/08/2023 | Q2 2023 | -$0.68 | $1.34 | 2.02 | $39.51 M | $294.12 M |
| 05/08/2023 | Q1 2023 | -$0.71 | -$0.80 | -0.09 | $35.14 M | |
| 02/27/2023 | Q4 2022 | -$0.78 | -$0.74 | 0.04 | $10.28 M | |
| 11/03/2022 | Q3 2022 | -$0.83 | -$0.84 | -0.01 | $17.02 M | $3.56 M |
| 08/08/2022 | Q2 2022 | -$0.52 | -$0.48 | 0.04 | $44.66 M | $52.48 M |
| 05/05/2022 | Q1 2022 | -$0.47 | -$0.52 | -0.05 | $42.14 M | |
| 02/28/2022 | Q4 2021 | -$0.41 | -$0.62 | -0.21 | $12.51 M | |
| 11/04/2021 | Q3 2021 | -$0.51 | -$0.69 | -0.18 | $30.28 M | $5.29 M |
| 08/04/2021 | Q2 2021 | -$0.37 | -$0.50 | -0.13 | $27.92 M | $22.94 M |
| 05/05/2021 | Q1 2021 | -$0.58 | $7.92 M | |||
| 02/26/2021 | Q4 2020 | $2.04 | $316.82 M | |||
| 11/05/2020 | Q3 2020 | $3.57 | -$0.54 | -4.11 | $494.27 M | $9.39 M |
| 08/07/2020 | Q2 2020 | -$0.61 | -$0.56 | 0.05 | $3.67 M | $5.85 M |
| 05/07/2020 | Q1 2020 | -$0.57 | -$0.55 | 0.02 | $3.60 M | |
| 02/27/2020 | Q4 2019 | -$0.53 | -$0.57 | -0.04 | $4.67 M | |
| 11/06/2019 | Q3 2019 | -$0.53 | -$0.48 | 0.05 | $9.33 M | $13.60 M |
Denali Therapeutics Inc. Earnings: Frequently Asked Questions
-
When is Denali Therapeutics Inc.'s earnings date?
Denali Therapeutics Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 5th, 2024 based off last year's report dates.
-
Did Denali Therapeutics Inc. beat their earnings estimates last quarter?
In the previous quarter, Denali Therapeutics Inc. (:DNLI) reported $-0.59 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.68 by $0.09.
-
How can I listen to Denali Therapeutics Inc.'s earnings conference call?
The conference call for Denali Therapeutics Inc.'s latest earnings report can be listened to online.
-
How can I read Denali Therapeutics Inc.'s conference call transcript?
The conference call transcript for Denali Therapeutics Inc.'s latest earnings report can be read online.
-
How much revenue does Denali Therapeutics Inc. generate each year?
Denali Therapeutics Inc. (:DNLI) has a recorded annual revenue of $330.53 M.
-
How much profit does Denali Therapeutics Inc. generate each year?
Denali Therapeutics Inc. (:DNLI) has a recorded net income of $330.53 M. Denali Therapeutics Inc. has generated $-1.06 earnings per share over the last four quarters.
-
What is Denali Therapeutics Inc.'s price-to-earnings ratio?
Denali Therapeutics Inc. (:DNLI) has a price-to-earnings ratio of -11.12 and price/earnings-to-growth ratio is 0.05.
